Goal:
03 - Sağlık ve Kaliteli Yaşam

Project Logo
Description
AMAÇ 3: SAĞLIKLI BİREYLER Çocuk ölüm oranlarının azaltılması, anne sağlığının iyileştirilmesi, HIV/AIDS, sıtma ve diğer hastalıklar ile mücadelede büyük aşama kaydetmiş durumdayız. 1990 yılından bu yana, önlenebilir çocuk ölümlerinde dünya genelinde %50’yi aşan azalma olmuştur. Anne ölümleri de dünya genelinde %45 azalmıştır. 2000 ile 2013 arasında HIV/AIDS bulaşma oranı %30 azalmış, 6,2 milyonu aşkın insan sıtmadan kurtarılmıştır. Bu ölümler; önleme ve tedavi, eğitim, aşı kampanyaları, cinsel ve üreme sağlığı hizmetleri vasıtasıyla önlenebilir. Sürdürülebilir Kalkınma Amaçları; AIDS, verem, sıtma ve diğer bulaşıcı hastalık salgınlarını 2030 yılına kadar ortadan kaldırmaya yönelik cesur bir taahhüttür. Amaç, herkesin genel sağlık hizmeti, güvenli ve erişilebilir ilaç ve aşıya kavuşmasını sağlamaktır. Aşı araştırma ve geliştirmelerinin desteklenmesi, bu sürecin vazgeçilmez bir parçasıdır.

Filters

2021 - 20224
Reset filters

Settings

Subject: COVID-19 × Author: Odabas, Ali Riza ×

Publication Search Results

Now showing 1 - 4 of 4
  • Thumbnail Image
    PublicationOpen Access
    Determinants of mortality in a large group of hemodialysis patients hospitalized for COVID-19
    (2021-01-14T00:00:00Z) Turgutalp, Kenan; Ozturk, Savas; Arici, Mustafa; Eren, Necmi; Gorgulu, Numan; Islam, Mahmut; Uzun, Sami; Sakaci, Tamer; Aydin, Zeki; Sengul, Erkan; Demirelli, Bulent; Ayar, Yavuz; Altiparmak, Mehmet Riza; Sipahi, Savas; Mentes, Ilay Berke; Ozler, Tuba Elif; Oguz, Ebru Gok; Huddam, Bulent; Hur, Ender; Kazancioglu, Rümeyza; Gungor, Ozkan; Tokgoz, Bulent; Tonbul, Halil Zeki; Yildiz, Alaattin; Sezer, Siren; Odabas, Ali Riza; Ates, Kenan; KAZANCIOĞLU, RÜMEYZA
    Background Maintenance hemodialysis (MHD) patients are at increased risk for coronavirus disease 2019 (COVID-19). The aim of this study was to describe clinical, laboratory, and radiologic characteristics and determinants of mortality in a large group of MHD patients hospitalized for COVID-19. Methods This multicenter, retrospective, observational study collected data from 47 nephrology clinics in Turkey. Baseline clinical, laboratory and radiological characteristics, and COVID-19 treatments during hospitalization, need for intensive care and mechanical ventilation were recorded. The main study outcome was in-hospital mortality and the determinants were analyzed by Cox regression survival analysis. Results Of 567 MHD patients, 93 (16.3%) patients died, 134 (23.6%) patients admitted to intensive care unit (ICU) and 91 of the ones in ICU (67.9%) needed mechanical ventilation. Patients who died were older (median age, 66 [57–74] vs. 63 [52–71] years, p = 0.019), had more congestive heart failure (34.9% versus 20.7%, p = 0.004) and chronic obstructive pulmonary disease (23.6% versus 12.7%, p = 0.008) compared to the discharged patients. Most patients (89.6%) had radiological manifestations compatible with COVID-19 pulmonary involvement. Median platelet (166 × 103 per mm3 versus 192 × 103 per mm3, p = 0.011) and lymphocyte (800 per mm3 versus 1000 per mm3, p < 0.001) counts and albumin levels (median, 3.2 g/dl versus 3.5 g/dl, p = 0.001) on admission were lower in patients who died. Age (HR: 1.022 [95% CI, 1.003–1.041], p = 0.025), severe-critical disease clinical presentation at the time of diagnosis (HR: 6.223 [95% CI, 2.168–17.863], p < 0.001), presence of congestive heart failure (HR: 2.247 [95% CI, 1.228–4.111], p = 0.009), ferritin levels on admission (HR; 1.057 [95% CI, 1.006–1.111], p = 0.028), elevation of aspartate aminotransferase (AST) (HR; 3.909 [95% CI, 2.143–7.132], p < 0.001) and low platelet count (< 150 × 103 per mm3) during hospitalization (HR; 1.864 [95% CI, 1.025–3.390], p = 0.041) were risk factors for mortality. Conclusion Hospitalized MHD patients with COVID-19 had a high mortality rate. Older age, presence of heart failure, clinical severity of the disease at presentation, ferritin level on admission, decrease in platelet count and increase in AST level during hospitalization may be used to predict the mortality risk of these patients.
  • Thumbnail Image
    PublicationOpen Access
    Middle-term outcomes in renal transplant recipients with COVID-19: a national, multicenter, controlled study
    (2022-02-01T00:00:00Z) Oto, Özgür Akın; Öztürk, Savaş; Arıcı, Mustafa; Velioğlu, Arzu; Dursun, Belda; Guller, Nurana; Şahin, İdris; Eser, Zeynep Ebru; Paydaş, Saime; Trabulus, Sinan; Koyuncu, Sumeyra; Uyar, Murathan; Ural, Zeynep; Sadioglu, Rezzan Eren; Dheir, Hamad; Koc, Neriman Sila; Ozer, Hakan; Durak, Beyza Algul; Gul, Cuma Bulent; Kasapoglu, Umut; Oguz, Ebru Gok; Tanrisev, Mehmet; Kuzgun, Gulsah Sasak; Mirioğlu, Şafak; Dervisoglu, Erkan; Erken, Ertugrul; Gorgulu, Numan; Ozkurt, Sultan; Aydin, Zeki; Kurultak, Ilhan; Ogutmen, Melike Betul; Bakirdogen, Serkan; Kaya, Burcu; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; MİRİOĞLU, ŞAFAK
    Background In this study, we evaluated 3-month clinical outcomes of kidney transplant recipients (KTR) recovering from COVID-19 and compared them with a control group. Method The primary endpoint was death in the third month. Secondary endpoints were ongoing respiratory symptoms, need for home oxygen therapy, rehospitalization for any reason, lower respiratory tract infection, urinary tract infection, biopsy-proven acute rejection, venous/arterial thromboembolic event, cytomegalovirus (CMV) infection/disease and BK viruria/viremia at 3 months. Results A total of 944 KTR from 29 different centers were included in this study (523 patients in the COVID-19 group; 421 patients in the control group). The mean age was 46 +/- 12 years (interquartile range 37-55) and 532 (56.4%) of them were male. Total number of deaths was 8 [7 (1.3%) in COVID-19 group, 1 (0.2%) in control group; P = 0.082]. The proportion of patients with ongoing respiratory symptoms [43 (8.2%) versus 4 (1.0%); P Conclusion The prevalence of ongoing respiratory symptoms increased in the first 3 months post-COVID in KTRs who have recovered from COVID-19, but mortality was not significantly different.
  • Thumbnail Image
    PublicationOpen Access
    Evaluation of Outcomes of Peritoneal Dialysis Patients in the Post-COVID-19 Period: A National Multicenter Case-Control Study from Turkey
    (2022-05-01T00:00:00Z) ÖZTÜRK, Savaş; Gursu, Meltem; Arici, Mustafa; Sahin, Idris; Eren, Necmi; Yilmaz, Murvet; Ozberk, Sumeyra; Sirali, Semahat Karahisar; Ural, Zeynep; Dursun, Belda; Yuksel, Enver; Uzun, Sami; Sipahi, Savas; Dal, Elbis Ahbap; Yazici, Halil; Altunoren, Orcun; Tunca, Onur; Ayar, Yavuz; Oguz, Ebru Gok; Yilmaz, Zulfikar; Kahvecioglu, Serdar; Asicioglu, Ebru; Oruc, Aysegul; Ataman, Rezzan; Aydin, Zeki; Huddam, Bulent; Dolarslan, Murside Esra; Azak, Alper; Bakirdogen, Serkan; Yalcin, Ahmet Ugur; Karadag, Serhat; Ulu, Memnune Sena; Gungor, Ozkan; Bakir, Elif Ari; Odabas, Ali Riza; Seyahi, Nurhan; Yildiz, Alaattin; Ates, Kenan; GÜRSU, MELTEM
    Introduction: There are not enough data on the post-CO-VID-19 period for peritoneal dialysis (PD) patients affected from COVID-19. We aimed to compare the clinical and laboratory data of PD patients after COVID-19 with a control PD group. Methods: This study, supported by the Turkish Society of Nephrology, is a national, multicenter retrospective case-control study involving adult PD patients with confirmed COVID-19, using data collected from April 21, 2021, to June 11, 2021. A control PD group was also formed from each PD unit, from patients with similar characteristics but without COVID-19. Patients in the active period of COVID-19 were not included. Data at the end of the first month and within the first 90 days, as well as other outcomes, including mortality, were investigated. Results: A total of 223 patients (COVID-19 group: 113, control group: 110) from 27 centers were included. The duration of PD in both groups was similar (median [IQR]: 3.0 [1.88-6.0] years and 3.0 [2.0-5.6]), but the patient age in the COVID-19 group was lower than that in the control group (50 [IQR: 40-57] years and 56 [IQR: 46-64] years, p < 0.001). PD characteristics and baseline laboratory data were similar in both groups, except serum albumin and hemoglobin levels on day 28, which were significantly lower in the COVID-19 group. In the COVID-19 group, respiratory symptoms, rehospitalization, lower respiratory tract infection, change in PD modality, UF failure, and hypervolemia were significantly higher on the 28th day. There was no significant difference in laboratory parameters at day 90. Only 1 (0.9%) patient in the COVID-19 group died within 90 days. There was no death in the control group. Respiratory symptoms, malnutrition, and hypervolemia were significantly higher at day 90 in the COVID-19 group. Conclusion: Mortality in the first 90 days after COVID-19 in PD patients with COVID-19 was not different from the control PD group. However, some patients continued to experience significant problems, especially respiratory system symptoms, malnutrition, and hypervolemia.
  • No Thumbnail Available
    PublicationMetadata only
    COVID-19 Infection in Peritoneal Dialysis Patients: A Comparative Outcome Study with Patients on Hemodialysis and Patients without Kidney Disease
    (2022-01-01T00:00:00Z) KAZANCIOĞLU, Rümeyza; Ozturk, Savas; TURGUTALP, KENAN; GÜRSU, Meltem; ARICI, MUSTAFA; ORUÇ, AYŞEGÜL; Ahbap, Elbis; GÖKÇAY BEK, SİBEL; Sengul, Erkan; Ogutmen, Melike Betul; Genek, Dilek Gibyeli; Ayli, Mehmet Deniz; Ayar, Yavuz; Onan, Engin; Karadag, Serhat; AŞICIOĞLU, EBRU; Yazici, Halil; ALTIPARMAK, MEHMET RIZA; TOKGÖZ, BÜLENT; Odabas, Ali Riza; TONBUL, HALİL ZEKİ; Sezer, Siren; Yildiz, Alaattin; ATEŞ, KENAN; KAZANCIOĞLU, RÜMEYZA; GÜRSU, MELTEM
    Objectives: There is limited data about coronavirus disease-19 (COVID-19) characteristics and results in peritoneal dialysis (PD) patients. This study aimed to investigate the characteristics and outcomes among PD patients and compare them with matched hemodialysis (HD) patients and a control group without kidney disease. Methods: We included 18 PD patients and consecutive age- and gender-matched 18 HD and 18 patients without kidney disease (control group) registered into the Turkish Society of Nephrology database including 1301 COVID-19 patients. We compared demographic, clinical, radiological, laboratory data, and outcomes namely intensive care unit (ICU) admission, mechanical ventilation, mortality, and composite outcome (death and/or ICU admission). Results: ICU admission, mechanical ventilation, and mortality rates in PD patients (27.8%, 22.2%, and 22.2%, respectively) and the HD group (16.7%, 11.1%, and 16.7%, respectively) were higher than the control group (11.1%, 11.1%, and 5.6%, respectively), but intergroup comparison did not reveal difference. A total of 11 (20.3%) patients had composite outcome (6 PD patients, 3 HD patients, and 2 patients in the control group). In Cox regression analysis, higher age and higher CRP level were related to increased risk of composite outcome. Adjusted rate of composite outcome in PD group was significantly higher than the control group (P =.050). This rate was similar in HD and control groups (P =.30). Conclusions: Combined in-hospital mortality and/or ICU admission of PD patients with COVID-19 was significantly higher than the control patients. There is a need for careful surveillance of PD patients for infection signs and prompt treatment of COVID-19.